Company: TELO
Filing Date: 2025-10-14
Form Type: 8-K
Source: 0001493152-25-017916
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-10-14
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer

Findings
complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1’s
consistent impact on cancer cell survival pathways.

Telomir
Pharmaceuticals, Inc. (NASDAQ: TELO) (“ Telomir” or the “ Company”) announced new laboratory findings demonstrating
that Telomir-1 reduced the survival of aggressive human pancreatic cancer (PANC-1) cells in vitro. Telomir-1 produced a concentration-dependent
decrease in cell viability and mitochondrial activity, suggesting influence on cellular pathways related to energy metabolism and oxidative
balance. These observations are consistent with previously reported data in triple-negative breast and prostate cancer models.

Similar
to TNBC, Telomir-1’s effects in pancreatic cancer cells were partially reversed additional metabolic or epigenetic mechanisms

Telomir-1
has previously been shown to influence tumor suppressor genes and iron-dependent histone demethylases that are relevant to pancreatic
cancer, including MASPIN (SERPINB5), RASSF1A, STAT1, KDM2B (FBXL10), and KDM6B (JMJD3). These genes and enzymes are known to govern DNA-methylation
balance, oxidative stress response, and cellular energy regulation and are frequently dysregulated in aggressive tumor types.

The
Company noted that pancreatic cancer is among the most difficult malignancies to treat, with a five-year survival rate of approximately
12 percent. Current standards of care - FOLFIRINOX and gemcitabine plus nab-paclitaxel - are limited by systemic toxicity and
the rapid development of resistance. Telomir-1 is being evaluated preclinically for its ability to modulate epigenetic and metabolic
regulators that contribute to cancer-cell survival and adaptation.

Telomir
plans to expand its preclinical research to additional cancer models, including leukemia, and to initiate in vivo validation studies
as part of its ongoing Investigational New Drug (IND) preparation.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                        TELOMIR